INT169697

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2010
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 35
Total Number 54
Disease Relevance 38.21
Pain Relevance 5.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Ephx2) Golgi apparatus (Ephx2) nucleolus (Ephx2)
peroxisome (Ephx2) cytoplasm (Ephx2)
Anatomy Link Frequency
plasma 4
kidney 4
blood 2
carotid artery 2
plaques 1
Ephx2 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 1128 99.68 Very High Very High Very High
Potency 164 99.08 Very High Very High Very High
Morphine 2 97.72 Very High Very High Very High
IPN 36 97.08 Very High Very High Very High
Hyperalgesia 2 96.88 Very High Very High Very High
cva 96 96.48 Very High Very High Very High
fibrosis 120 95.52 Very High Very High Very High
withdrawal 2 95.32 Very High Very High Very High
Pain 68 94.68 High High
Bioavailability 52 94.32 High High
Disease Link Frequency Relevance Heat
Atherosclerosis 1696 99.96 Very High Very High Very High
INFLAMMATION 1160 99.68 Very High Very High Very High
Albuminuria 200 99.60 Very High Very High Very High
Renal Failure 180 99.50 Very High Very High Very High
Hypertension 828 99.44 Very High Very High Very High
Aneurism 252 99.44 Very High Very High Very High
Chronic Renal Failure 200 99.38 Very High Very High Very High
Renal Disease 140 99.22 Very High Very High Very High
Disease 260 98.64 Very High Very High Very High
Disorder Of Lipid Metabolism 384 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, inhibition of sEH has been proposed as a therapeutic target to treat hypertension and its complications [13].
Negative_regulation (inhibition) of sEH associated with hypertension
1) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.70 Pain Relevance 0.30
Thus, improvement of endothelial function can also contribute to the antiatherosclerotic effects of sEH inhibitors.
Negative_regulation (inhibitors) of sEH
2) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.31 Pain Relevance 0.03
The antiatherosclerotic effect of AEPU was accompanied by an inhibition of sEH activity measured by a significant increase in linoleic and AA epoxides, as well as the ratios of EETs to DHETs.
Negative_regulation (inhibition) of sEH
3) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.64 Pain Relevance 0
In functional studies, K55R increases sEH activity, whereas another common polymorphism, Arg287Gln (R287Q), reduces sEH activity.
Negative_regulation (reduces) of sEH
4) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.04 Pain Relevance 0
The reduction in the atherosclerotic lesion area was inversely correlated with the ratios of 11, 12-EET/DHET and 14, 15-EET/DHET, suggesting that the efficacy corresponds to the inhibition of sEH.
Negative_regulation (inhibition) of sEH associated with atherosclerosis
5) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.42 Pain Relevance 0.12
In addition to monotherapy, sEH inhibitors may also be combined with other existing drugs for atherosclerotic vascular disease.
Negative_regulation (inhibitors) of sEH associated with atherosclerosis
6) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.16 Pain Relevance 0.10
The biological effects seen in these studies can be attributed to inhibition of sEH activity evidenced by an increase in plasma EET to DHET ratio.
Negative_regulation (inhibition) of sEH in plasma
7) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.29 Pain Relevance 0.40
Its potency and pharmacokinetics indicate that it should inhibit the sEH in humans at a fraction of the doses used therapeutically for cancer [69].
Negative_regulation (inhibit) of sEH associated with cancer and potency
8) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.37 Pain Relevance 0.29
Inhibitors of sEH can enhance these effects by stabilizing EETs and other lipid epoxides and by reducing some proinflammatory diols [12].
Negative_regulation (Inhibitors) of sEH
9) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.59 Pain Relevance 0.23
Zhang et al. [3••] demonstrated that sEH inhibition lowered circulating LDL by 30%, elevated HDL by 43%, and elevated the HDL to LDL ratio by 96%, which could contribute, at least partially, to the antiatherosclerotic effects of sEH inhibitors.
Negative_regulation (inhibition) of sEH associated with disorder of lipid metabolism
10) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.06 Pain Relevance 0
These two independent reports provide direct and compelling evidence that sEH plays an important role in the pathogenesis of atherosclerosis development and aneurysm formation, suggesting that inhibition of sEH may be a promising therapeutic intervention in these indications.
Negative_regulation (inhibition) of sEH associated with atherosclerosis and aneurism
11) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.09 Pain Relevance 0.07
Inhibition of sEH in Animal Models of Atherosclerosis
Negative_regulation (Inhibition) of sEH associated with atherosclerosis
12) Confidence 0.59 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 1.19 Pain Relevance 0
Importantly, this notion is also supported by data on human polymorphisms: In kidney transplanted patients a gene polymorphism leading to reduced sEH activity was linked to allograft dysfunction and decreased graft survival [47].
Negative_regulation (reduced) of sEH in kidney
13) Confidence 0.55 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2915917 Disease Relevance 0.57 Pain Relevance 0.07
This effect was equally strong as the increase of EETs in response to sEH inhibition by cAUCB in sham animals.
Negative_regulation (inhibition) of sEH
14) Confidence 0.55 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2915917 Disease Relevance 0.15 Pain Relevance 0
sEH inhibition does not prevent progression of renal damage
Negative_regulation (inhibition) of sEH
15) Confidence 0.55 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2915917 Disease Relevance 0.39 Pain Relevance 0
No significant effects were seen on DHET plasma levels excluding product inhibition of sEH as a possible mechanism for EET accumulation in chronic renal failure.
Negative_regulation (inhibition) of sEH in plasma associated with chronic renal failure
16) Confidence 0.55 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2915917 Disease Relevance 0.17 Pain Relevance 0.04
Inhibitors of sEH reduce inflammation and prevent the development of atherosclerotic plaques, presumably via an increase in EETs and other epoxy lipids, as well as a decrease in the corresponding diols [3••, 4••].
Negative_regulation (Inhibitors) of sEH in plaques associated with atherosclerotic plaque and inflammation
17) Confidence 0.51 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.73 Pain Relevance 0.15
The most useful sEH inhibitors to date are competitive transition state inhibitors of sEH [9, 11].
Negative_regulation (inhibitors) of sEH
18) Confidence 0.51 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.33 Pain Relevance 0.15
Inhibition of sEH and 5/6-Nx results in increased plasma level of lipoxygenase products
Negative_regulation (Inhibition) of sEH in plasma
19) Confidence 0.48 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2915917 Disease Relevance 0.23 Pain Relevance 0.08
Taken together, it appears that the effects of sEH inhibition on VSMC proliferation and migration and on neointimal formation after vascular injury are controversial.


Negative_regulation (inhibition) of sEH associated with vasculitis
20) Confidence 0.43 Published 2010 Journal Curr Atheroscler Rep Section Body Doc Link PMC2857794 Disease Relevance 0.62 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox